Q-omics provides the consensus-scored LILRA4 profile across patient tissues and cancer cell-line models. LILRA4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LILRA4 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, LILRA4 RNA expression shows 17,362 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where LILRA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LILRA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LILRA4 survival associations across molecular data types. LILRA4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LILRA4 RNA expression–survival associations across cancer types. High LILRA4 expression shows favorable associations in KIRC, HNSC, LUAD, CESC, SCLC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LILRA4 RNA expression.
This table summarizes LILRA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LILRA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LILRA4 shows lower tumor expression in COAD and LUSC and higher tumor expression in KIRC, BRCA, STAD and KIRP. The COAD box plot shows higher LILRA4 RNA expression in normal versus tumor tissue (log2 FC = −1.363, t-test p < 0.001).
This table shows molecular features associated with LILRA4 in patient tissues and cancer cell lines. In patient samples, LILRA4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LILRA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BREAST.
